WallStSmart

Coca-Cola European Partners PLC (CCEP)vsCoca-Cola Femsa SAB de CV ADR (KOF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola Femsa SAB de CV ADR generates 1296% more annual revenue ($291.75B vs $20.90B). CCEP leads profitability with a 9.3% profit margin vs 8.2%. CCEP appears more attractively valued with a PEG of 2.85. CCEP earns a higher WallStSmart Score of 57/100 (C).

CCEP

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.5Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.55

KOF

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 7.5Value: 4.7Quality: 6.5
Piotroski: 2/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCEPUndervalued (+57.3%)

Margin of Safety

+57.3%

Fair Value

$228.38

Current Price

$96.08

$132.30 discount

UndervaluedFair: $228.38Overvalued
KOFSignificantly Overvalued (-51.2%)

Margin of Safety

-51.2%

Fair Value

$74.47

Current Price

$97.03

$22.56 premium

UndervaluedFair: $74.47Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP4 strengths · Avg: 8.8/10
EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Return on EquityProfitability
22.9%9/10

Every $100 of equity generates 23 in profit

Revenue GrowthGrowth
20.0%8/10

Revenue surging 20.0% year-over-year

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

KOF2 strengths · Avg: 8.0/10
P/E RatioValuation
15.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

CCEP4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Debt/EquityHealth
1.503/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.852/10

Expensive relative to growth rate

KOF4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.4%4/10

2.4% revenue growth

EPS GrowthGrowth
3.0%4/10

3.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
20.382/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on EPS Growth, Return on Equity, Revenue Growth. Revenue growth of 20.0% demonstrates continued momentum.

Bull Case : KOF

The strongest argument for KOF centers on P/E Ratio, Price/Book.

Bear Case : CCEP

The primary concerns for CCEP are Altman Z-Score, Debt/Equity, Piotroski F-Score.

Bear Case : KOF

The primary concerns for KOF are Revenue Growth, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

CCEP profiles as a growth stock while KOF is a value play — different risk/reward profiles.

KOF carries more volatility with a beta of 0.48 — expect wider price swings.

CCEP is growing revenue faster at 20.0% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

CCEP scores higher overall (57/100 vs 54/100) and 20.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Coca-Cola Femsa SAB de CV ADR

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola FEMSA, SAB de CV, a franchise bottler, produces, markets, sells and distributes Coca-Cola brand beverages. The company is headquartered in Mexico City, Mexico.

Visit Website →

Want to dig deeper into these stocks?